The CATT Trial began recruiting patients in January 2008. It has two primary purposes:
- Compare the safety and efficiency of Lucentis and Avastin
- Determine whether or not as-needed dosing can produce a visual result that is as robust as what has previously been demonstrated with fixed dosing
The results of the second year of the Comparison of Age-related macular degeneration Treatment Trials (CATT) indicate that bevacizumab (Avastin®) is equivalent to ranibizumab (Lucentis®) in the treatment of wet age-related macular degeneration through two years when using similar dosing regimes. The two-year CATT results confirm that both Avastin and Lucentis are safe and effective therapies for wet age-related macular degeneration. Beyond the clinical findings of the study, the cost differences between treatments may have implications for both patients and physicians. One dose of Lucentis costs approximately $2,000 while Avastin cost about $50 per dose. Both drugs are manufactured by GeneTech.
The study chairman is David F. Martin, M. D., at Emory University.
Gene RPE65 replacement therapy in Leber Congenital Amaurosis (LCA) is in clinical trials.
For more information, contact:
Dr. John Guy, M. D.
University of Florida, Department of Ophthalmology
P.O. Box 100284
Gainsville, FL 32610-0284
Investigational Therapies For Dry Age Related Macular Degeneration
Support for a paradigm that links aberrant complement activation with AMD was revealed in studies associating AMD with three genes, including factor H. Collectively, the three gene variations account for nearly 75% of all AMD cases in European and North American populations. The unanswered question is whether inhibiting complement so late in the disease process will alter disease progression or vision loss.
This agent halts accumulation of lipofuscin and toxic vitamin A metabolites. A two-year, phase 2 dose-ranging trial by Sirion is under way.
The National Eye Institute (NEI) is adding lutein and zeaxanthin to the Age Related Eye Disease Study (AREDS) formulation and is testing it in patients.
Ciliary Neurotrophic Factor (CNTF)
The company Neurotech is testing an implantable drug delivery system releasing the growth factor CNTF into the eye over time.
The company Potentia Pharmaceuticals is testing this complement inhibitor, which may block inflammation and angiogenic factors seen in age related macular degeneration (ARMD).
The company Othera and NEI are testing this agent, which may protect retinal pigment epithelium (RPE) cells and photoreceptors from oxidative damage and angiogenesis stimulated by vascular endothelial growth factor (VEGF).
An ongoing study to test the drug Copaxone, which is used in treating multiple sclerosis, is being evaluated for its use in preventing progression of dry to the wet form of age related macular degeneration (ARMD).
Complement Inhibition with Eculizumab
Information: (305) 326-6148
Information: (865) 483-6399
Sirolimus to Treat Geographic Atrophy
Information: (800) 411-1222
Topical Treatment with AL-830913
RN6G to Treat Dry Age-related Macular Degeneration
Information: (800) 718-1021
Fluocinolone Acentonide Intravitreal Inserts in Geographic Atrophy
ACU-02 0for Dry Age-related Macular Degeneration